Atilal natriuretic peptide and dopamine in a rat model of lschemic acute renal failure. Atrial natriuretic peptide (ANP) has been shown to reverse experimental models of ischemic acute renal failure (ARF).
measurements revealed single nephron glomerular filtration rate (SNGFR) in Group 3 to be twice that in Group 2 and actually greater than sham-ARF rats (P < 0.05), while it remained similar to Group 2 in the Group 4 rats. The increase in SNGFR in the APIII-D treated ARF rats was due to marked increases in both glomerular capillary hydraulic pressure (P0) and glomerular plasma flow rate (QA) as the result of a major decline in afferent arteriolar resistance (RA) compared to the other three groups. It was concluded that the combination of i.v. AP III and D is effective in restoring GFR in an ischemic model of ARF while preventing systemic hypotension and maintaining RBF. The dominant effect on glomerular hemodynamics, attributable primarily to AP III, was a reduction in RA causing striking increases in both P0 and QA. norepinephrine in rats. While these studies suggest the possibility that clinical acute renal failure (ARF) could be reversed by pharmacological infusion of ANP, therapeutic enthusiasm has been tempered by the observation that a marked reduction in arterial pressure may be associated with ANP infusion. With intravenous doses of AP III effective in restoring renal function, Nakamoto et al [1] reported that mean systemic arterial pressure (MAP) fell to approximately 70 mm Hg. Arterial pressures were not given in the studies of Shaw et al [2] and Schafferhans et al [3] ; however, it is possible that arterial pressure reductions were encountered since both the intrarenal infusion rates and total ANP doses were greater than those used by Nakamoto et al [11. A number of other studies also have shown a substantial reduction in arterial pressure in both humans and experimental animals at infusion rates of ANP comparable to those that have been efficacious in acute renal ischemia 14, 5] . Thus, given the tenuous hemodynamic status of many ARF patients, the clinical potential of ANP could be limited unless the associated reduction in arterial pressure is prevented.
In the present study, we tested the effects of the combined use of ANP and dopamine (D) intravenously following 55 minutes of bilateral renal artery clamping in Munich-Wistar rats. ANP was given at a dose previously shown to be necessary to improve ischemic injury but reduce MAP [11 and dopamine was given at a dose sufficient to prevent the reduction in MAP without compromising renal blood flow. The effect on both whole kidney function and glomerular dynamics was measured after four hours of this treatment regimen and compared to that of saline infusion or dopamine alone.
Methods
Littermate male Munich-Wistar rats weighing between 250 and 300 g were prepared for whole kidney clearance and micropuncture studies as described elsewhere [6, 71 . Following pentobarbital anesthesia (60 mg/kg i.p.), a tracheostomy was performed and catheters were placed in the left jugular and femoral veins and femoral artery. The left kidney was exposed through a flank incision, dissected free from surrounding tissue and placed in a lucite cup. The femoral vein catheter was advanced into the left renal vein by a technique described previously for this laboratory [81. The left ureter was catheterized for urine collections. Arterial blood pressure was continuously monitored with an electronic transducer (Statham model P23Db, Gould, Inc., Oxnard, California, USA) and a direct writing recorder (model 7702B, Hewlett-Packard Co., Palo Alto, California, USA).
Rats were then divided into four experimental groups as follows: Group 1: (N = 6) Sham-ARF time-controlled animals Following manipulation and dissection of the renal pedicle from surrounding tissue, an intravenous infusion of 0.9 per cent saline was given at 1.5 mI/hr for 55 minutes. Thereafter, the infusion rate was increased to 2.8 mI/hr for four hours. Three hours into infusion, inulin and para-aminohippurate (PAH) were added to give plasma levels of 50 to 100 and 2 to 4 mg/dl, respectively. At the end of the four-hour infusion, tail vein and renal venous blood samples were obtained between 50-pi timed urine collections for measurement of sodium, inulin and PAH.
Thereafter, at least five two-minute collections of proximal tubular fluid were made with 8 m outside diameter oil-filled pipettes. In order not to introduce examiner bias, individual nephrons to be studied were chosen by accepting the tubule which lay beneath a cross-hair placed in the ocular of the microscope. Subsequent nephrons were selected in the same manner after shifting blindly to a new microscopic field. With a servo-null pressure monitoring device (Instruments for Physiology and Medicine, San Diego, California, USA), an electronic transducer (Statham model P23Db, Gould, Inc.), hydraulic pressures were measured in glomerular capillaries (PGC), efferent star vessels (PE), and proximal tubules (PT). At least three measurements were made in each animal. Because it was discovered that dopamine in plasma samples factitiously increases intensity of both the phthalaldehyde flurometric [9] and Lowry colormetric [10] measurements of microprotein concentration, whole kidney filtration fraction derived from inulin extraction was used as an estimate of single nephron filtration fraction (SNFF). Comparison of SNFF determined from femoral artery and efferent arteriole plasma protein by the phthalaldehyde technique with whole kidney FF in rats not infused with dopamine revealed the latter to be consistently 5 to 10 per cent lower. However, the magnitude of animal to animal differences were identical. Therefore, because of the minimal absolute differences in individual animals and the same inter-animal differences using the two determinations of filtration fraction, substitution of whole kidney for single nephron value was considered justified. Afferent arteriolar protein content (CA) was determined from the direct biuret measurement of femoral artery plasma protein [11] which was not altered by dopamine. Efferent arteriolar protein content (CE) was calculated from the femoral artery protein content and the whole kidney filtration fraction. This technique has been used previously by our laboratory [8] and other investigators [12, 131 . At the conclusion of the micropuncture measurements, tail and renal vein blood and timed urine collections were repeated for sodium, inulin and PAH. If the pre-and post-micropuncture values of urinary sodium excretion rate (UnaV), inulin clearance (CIN), and para-aminohippurate clearance (CPAH) (adjusted for extraction fraction) differed more than 10 per cent, the experiment was discarded.
Group II rats: (N = 6) Saline-treated ARF controls Except for 55 minutes of bilateral renal artery clamping prior to the four hours of 0.9 per cent saline infusion, these animals were treated identically to Group I. Infusion rate was adjusted every 30 minutes to match urine flow rate (V).
Group III rats (N = 6)
These animals underwent the same protocol as Group II, but were infused with AP III (Bachem, Inc., Torrance, California, USA) at 0.2 sg/kg/min, the dose that reversed ischemic injury but lowered MAP in the study of Nakamoto Ct al [1] , and D (Lypho Med., Inc., Melrose Park, Illinois, USA) at a rate sufficient to maintain MAP > 100 mm Hg following the 55 minutes of bilateral renal artery clamping. Infusion varied from 0.8 to 9.0 sg/kg min'. As in Group II, 0.9 per cent saline infusion was adjusted every 30 minutes to match V.
Group IV rats: (N = 6) Dopamine controls Rather than a combined infusion of AP III and D, only D was infused for four hours following 55 mm bilateral renal artery clamping. D was infused at a maximal dose that did not elevate MAP above 120mm Hg and ranged from 0.4 to 1.6 g/k min'; however, D could not be infused at the upper end of infusion range when given with AP III without producing MAP above 120 mm Hg.
AP III alone was not infused because of the profound reduction in MAP found in preliminary studies negating meaningful comparisons of micropuncture results and because these experiments had previously been performed by others [2, 3] and were considered to be an adequate basis for comparison with the present study.
Analytic techniques
Plasma and urine inulin and PAH were measured with a Technicon Autoanalyzer (Technicon Instruments Corp., Tarrytown, New York, USA). Tubular fluid inulin was estimated by the micromethod of Vurek and Pegram [14] as modified for this laboratory [10] . Urinary sodium concentration was determined by flame photometry.
Plasma colloid osmotic pressure (IT) was determined from the Landis and Pappenheimer formula [15] : 1r(mm Hg) = 2.1C + 0.16 C2 + 0.001 C3 where C represents total protein concentration (in grams per deciliter).
Single nephron filtration rate (SNGFR) was calculated from the formula:
where CR represents tubular fluid collection rate and TF/P1 the tubular fluid to plasma inulin ratio. where CA and CE denote afferent and efferent arteriolar protein concentrations, respectively, based on femoral artery protein content and the whole kidney filtration fraction derived from inulin extraction.
Glomerular plasma flow rate was QA = SNGFR/SNFF where QA refers to glomerular plasma flow rate.
Blood flow rate per single afferent arteriole or glomerulus was calculated as GBF = QA/(l -HctA) where HctA, the hematocrit of afferent arteriolar blood, was taken to be equal to the femoral arterial hematocrit. Efferent arteriolar blood flow rate was determined as:
Resistance per single afferent arteriole was derived from the formula:
where the factor 7.962 x 1010 is used to give resistance in units of dynes/sec/cm5 when MAP and P0 are expressed in milliliters of mercury and GBF in nanoliters per minute. Resistance per single afferent arteriole was derived from the formula:
here E is the pressure recorded in the efferent "star" vessel.
Mean glomerular transcapillary pressure difference was calculated as:
AP = GC -
The ultrafiltration coefficient (Kf) was determined by the block iteration described by Blantz [16] .
Data are expressed as means SD. Overall group comparisons were by analysis of variance for multiple groups and individual intergroup comparisons were by Dunnett's method when comparing ARF groups to the sham-ARF control group, and Scheffe's method when comparing ARF groups to each other [17],
Results
Body weights, hematocrits, mean arterial blood pressures and whole kidney function parameters are shown in Table 1 .
Body weights are similar in all groups. Mean hematocrit was slightly higher in the D-treated ARF rats than in the sham-ARF control or saline-treated groups. Mean arterial pressure was maintained > 100 mm Hg during the four hour infusion in the AP III-D treated ARF rats. This MAP level was not different from that in the saline-treated animals. Both sham-ARF control and D-treated ARF rats had significantly higher MAP than the saline and AP HI D-treated ARF groups. In both NP III-D and D-treated ARF rats RBF was increased compared to the saline-treated ARF group. RBF was also higher in the AP III-D treated ARF than the sham-ARF control group. RBF in the saline-treated ARF rats had recovered to the same level as in sham-ARF controls. Mean GFR was 48 per cent of that in sham-ARF controls in the saline-treated ARF animals but was increased to that in sham-ARF control rats in the AP III-D group. While GFR in the D-treated ARF group was slightly greater than that in saline-treated ARF rats, it remained significantly lower than that in AP III-D infused ARF animals. Urine flow rate was strikingly increased in the AP III-D ARF animals.
The mean level of V was more than sixfold greater than sham-ARF controls or the other two ARF groups. Urinary sodium excretion rate (UNaY) was also markedly increased in the AP III-D treated ARF rats as was the fractional excretion of sodium (FENa). Glomerular filtration rates, urine flow rates and urine sodium excretion rates are illustrated in Figure 1 .
Micropuncture studies are shown in Table 2 . Single nephron glomerular filtration rate was reduced by 40 per cent in salinetreated ARF rats compared to sham-ARF controls. In the AP III-D treated ARF rats, however, SNGFR not only was higher than in saline-treated ARF rats but was actually greater than in the sham-ARF control animals. The SNGFR in the D-treated ARF group was not different from the reduced level in salinetreated ARF rats.
Of the determinants of SNGFR, elevations in both SP and QA were responsible for the increase in SNGFR in the AP III-D treated AFR animals. The AP level was due primarily to an increased P0, which was 17 mm Hg higher than the sham-ARF control value, and at least 10 mm Hg greater than the conesponding mean GC in saline-treated and D-treated ARF rats. Glomerular plasma flow was nearly 100 nllmin greater than that in sham-ARF or other ARF treatment groups. In the D-treated ARF group, P0c was higher than in sham-ARF rats, but mean was similar due to the variable tendency for P1-to be increased in ARF rats. Comparative SNGFR. GC, T and QA values are shown in Figure 2 .
The marked increases in P0c and QA in the AP III-D treated ARF rats were due primarily to changes in RA. RA was strikingly lower than in the other three groups. Mean R in AP III-D treated ARF rats tended to be lower than that in salinetreated ARF rats; however, the difference was not significant. RE in AP III-D treated group also was not significantly less than in sham-ARF or D-treated ARF animals. There were no differences inKF values among any of the four experimental groups.
Since i.W was greater than ir in all groups, all Kf determinations represented unique values. Efferent star vessel hydraulic pressure, as an index of efferent arteriolar pressure (PE)' was significantly elevated in AP III-D treated ARF rats. All other group means of E were similar.
Absolute proximal reabsorption was lower in saline-treated ARF rats than in sham-ARF controls. However, no other significant differences in iv were detected. Means of proximal tubular fractional reabsorption tended to be lower in the AP III-D and D-treated ARF rats. However, the animal to animal variability within the groups negated detection of overall or pairwise significant comparative differences.
Discussion
Atrial natriuretic peptide has been shown to have exciting potential in reversing the effects of acute renal ischemia [1] [2] [3] . However, the systemic hypotensive effect of this agent may be a drawback to its clinical use [1, 4, 51 . The present study demonstrates that the combination of ANP and dopamine can correct the decrement in GFR induced by 55 minutes of RAO while maintaining mean arterial pressure above 100 mm Hg.
The parenteral infusion of ANP and dopamine may be a practical as well as efficacious combination in the treatment of ischemic ARF, since it can be employed after, rather than before, the ischemic insult and it does not alter systemic hemodynamics, which is a major concern in the clinical setting.
The results indicate that while dopamine was responsible for supporting systemic arterial pressure, AP III was of greater significance in reversing the ischemia-induced reduction of GFR. Dopamine given alone in a dosage range similar to that used when combined with AP III significantly increased both RBF and GFR when compared to ARF rats treated with saline only. However, the improvement in GFR with dopamine was less than one-third of that with AP III and D combined. Mean GFR with the combined AP III-D treatment was actually greater than in sham-ARF control animals. The improvement in GFR with ANP following renal ischemia to levels the same as or r::
higher than non-ischemic controls has been reported previously by other investigators [1, 3] . _____
The mechanism of elevation of post-ischemic GFR by AP III-D was clarified by the experiments measuring glomerular dynamics. There were marked increases in both GC and QA that resulted in a greater than twofold increase in SNGFR compared to the saline-treated ARF rats. While zP would generally play a greater and QA a lesser role in the filtration disequilibrium conditions found in this study [18] , the magnitude of increase in QA accounted for nearly one-half of the SNGFR increase. The changes in both P and QA in AP III-D treated ARF animals were due primarily to a profound reduction in RA. Afferent arteriolar resistance was not increased in saline-treated ARF rats four hours after blood reflow compared to sham-ARF controls, indicating that there was not a marked increase in vasoconstrictor activity at this site. Nonetheless, infusion of AP III-D resulted in a 60 per cent reduction in mean RA even though the vasodilator effect of ANP had been noted previously to be most profound in angiotensin or norepinephrifle pre-constricted vessels [19] . While it is possible that the substantial decrease in RA in this study was due to a synergistic effect of dopamine with AP III, dopamine alone in the doses that were used did not reduce afferent arteriolar resistance and, therefore, it must be assumed that AP III was the dominant factor in afferent arteriolar relaxation. In preliminary experiments, dopamine alone given at the highest levels as when combined with AP III actually caused an increase in RA compared to normal controls. Efferent arteriolar resistance in AP III-D treated ARF rats was not different from that in saline-treated ARF animals. Direct measurements by Ichikawa et al [20] in normal rats have indicated that R was increased by ANP. However, the effect of dopamine combined with AP Ill may have attenuated an ANP-induced elevation of RE. On the other hand, it should be noted that the absence of a significant A decrease in Rt was itself a contributing factor in the increase in P6c in addition to the aforementioned reduction in RA.
There was an increase in whole kidney GFR but no change in 0 SNGFR in the D-treated ARF animals. While this difference 6 may reflect a sample size error in the latter measurement, the consistency of this difference in all rats suggests a relative .
redistribution of renal blood flow to sub-surface nephrons secondary to dopamine as has been found with other vasodilators [21] . The mechanism of the striking natriuresis observed in the AP 20 II!-D treated ARF rats was likely complex in a post-ischemic model with tubular injury. While the increase in GER was, no doubt, a major factor in the natriuresis, tubular dysfunction and direct effects of AP HI probably contributed as well. In experimental animals with normally functioning tubules, a doubling B of GFR is associated with only a two-to fourfold increase in sodium excretion, indicative of whole kidney glomerulo-tubular 60 balance [22] . However, in the AP III-D treated ARF rats in this study where there was a doubling of GFR compared to salinetreated ARF animals, sodium excretion increased 14-fold. It is 40 not possible to separate clearly the effects on tubular sodium reabsorption of ANP or D from those of ischemic damage. On E the other hand, the markedly greater fractional, as well as 20 absolute, sodium excretion in the AP III-D treated ARF rats compared to both the saline and D-treated ARF groups suggests strongly that there was a direct effect of AP III to decrease tubular sodium reabsorption. The natriuretic effect of AP III in this ARF model was beyond at least the accessible proximal convoluted tubule, since neither absolute nor fractional reabsorption of sodium in the proximal tubule differed among the ARF groups treated with saline, AP III-D or D alone. However, the tendency for decreased fractional volume reabsorption in the accessible proximal convoluted tubule coupled with an increased P in the AP III-D treated ARF rats suggests that (13) . The difference between glomerular capillary and proximal tubular pressure is the net glomerular transcapillary hydraulic pressure. *Different from corresponding value in other ARF groups at P < 0.01. peritubular capillary hydraulic forces may have played a role in decreasing volume reabsorption in the late proximal tubule beyond the micropuncture sites. Recent reports in normal rats also indicate that there is a substantial tubular effect of ANP beyond the proximal convoluted tubule and most likely is in the loop of Henle, collecting tubules and collecting ducts [23, 24] . Dopamine also has been associated with a natriuresis that is independent of RBF or GFR [25] . The contribution of dopamine to the natriuresis induced by AP III-D, however, was probably small, as indicated by the absolute and fractional sodium excretion in the D-treated ARF rats which were much less than with the combined AP III-D infusion.
In addition to the maintenance of systemic MAP, the combination of ANP and dopamine may have relatively specific beneficial effects on at least two of the most frequently reported pathogenetic mechanisms reducing GFR in ischemic ARF, namely, tubular obstruction [26] and increased renovascular resistance [27] . Tubular obstruction decreases glomerular filtration by increasing proximal tubular pressure and lowering the net transcapillary hydraulic pressure. ANP, which is reported to increase GC by decreasing RA and increasing RE, elevates the net transcapillary hydraulic pressure [20] . On the other hand, ANP alone does not consistently decrease total renovascular resistance because of the reciprocal effects on pre-and postglomerular resistances and, therefore, does not increase glomerular plasma flow [20] . However, dopamine appears to attenuate the efferent arteriolar vasoconstriction and possibly enhances the afferent arteriolar vasodilatation induced by ANP, thereby increasing glomerular plasma flow. Thus, ANP plus dopamine directly increases two of the determinants of glomerular ultrafiltration, namely, transcapillary glomerular hydraulic pressure and glomerular plasma flow, that are depressed by the pathogenetic processes in ischemic ARF. This study did not address the post-infusion intermediate or long term effects of ANP and dopamine in ARF, since the thrust of the experiments was to examine the compatibility and physiologic effects of combining those agents and the supportive role of dopamine in ANP therapy to reverse ARF. However, in the studies of Shaw et al [2] and Nakamoto et al [1] in which ANP was infused for from one to four hours after 45 to 60 minutes of renal artery clamping, serum creatinines were normal at 24 and 48 hours, respectively, compared to three-and fourfold increases in untreated ARF rats. Moreover, the former study [2] showed marked improvement in the histologic appearance at 48 hours, particularly inner cortical and outer medullary peritubular hyperemia. On the other hand, the presence of tubular casts was not significantly changed. Since the AP III-D infusion in the present investigation showed nearly identical if not slightly greater immediate improvements in GFR and urine flow rate compared to the above studies [1, 2] , it is reasonable to assume that the post-infusion course would have been similarly impressive.
In summary, the addition of dopamine in the treatment of ischemic ARF effectively corrects the systemic hypotensive effect of ANP that could impede its clinical use in attenuating the course of ARF. Moreover, dopamine may also enhance the positive effects of ANP on the determinants of glomerular ultrafiltration. Thus, ANP and dopamine infusion potentially may be a therapeutically beneficial combination in human ischemic ARF. This combined intravenous maneuver avoids the invasive intrarenal infusion of ANP; the hypotensive effect of ANP and dopamine also appears to enhance the protective effect of ANP in experimental ARF.
